P-tau231 has been demonstrated to be the earliest p-tau biomarker to abnormally emerge during preclinical AD stages, even prior to detectable Aβ pathology by positron emission tomography (PET) [1, 30, 45]. The gene discussed is MAPT; the disease is Alzheimer disease.